Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases-Reference-Cited by-同舟云学术

Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases

Published:2021-01-11 Issue:1 Volume:50 Page:151-165
ISSN:0300-5127
Container-title:Biochemical Society Transactions
language:en
Short-container-title:

Author:

Narayanan Anoop¹,Toner Shay A.¹,Jose Joyce¹²^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania 16802, U.S.A

2. Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania 16802, U.S.A

Abstract

SARS-CoV-2, the coronavirus responsible for the current COVID-19 pandemic, encodes two proteases, 3CLpro and PLpro, two of the main antiviral research targets. Here we provide an overview of the structures and functions of 3CLpro and PLpro and examine strategies of structure-based drug designing and drug repurposing against these proteases. Rational structure-based drug design enables the generation of potent and target-specific antivirals. Drug repurposing offers an attractive prospect with an accelerated turnaround. Thus far, several protease inhibitors have been identified, and some candidates are undergoing trials that may well prove to be effective antivirals against SARS-CoV-2.

Publisher

Portland Press Ltd.

Subject

Biochemistry

Link

https://portlandpress.com/biochemsoctrans/article-pdf/50/1/151/930342/bst-2021-1180.pdf

Reference74 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin;Nature,2020

2. A new coronavirus associated with human respiratory disease in China;Nature,2020

3. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination;Sci. Adv.,2021

4. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant;N. Engl. J. Med.,2021

5. Molnupiravir, an oral antiviral treatment for COVID-19;medRxiv,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (Mpro) using molecular docking and deep learning methods;Computers in Biology and Medicine;2023-05

2. In silico identification and molecular dynamic simulations of derivatives of 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide against main protease 3CLpro of SARS-CoV-2 viral infection;Journal of Molecular Modeling;2023-04-05

3. Proteolytic cleavage and inactivation of the TRMT1 tRNA modification enzyme by SARS-CoV-2 main protease;2023-02-13

4. A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2;Scientific Reports;2023-01-10

5. Small molecules in the treatment of COVID-19;Signal Transduction and Targeted Therapy;2022-12-05